Jiwei Liu

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

Medicine, Oncology, Pharmacotherapy +11

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · The Lancet Respiratory Medicine · 2022 · 230 citations

Medicine, Oncology, Pharmacology +13

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

Yuankai Shi, Junling Li, Shucai Zhang et al. · PLoS ONE · 2015 · 205 citations · Full text

Medicine, Molecular Medicine, Oncology +14

USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma

Zhen Ning, Xin Guo, Xiaolong Liu et al. · Nature Communications · 2022 · 178 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial–mesenchymal transition and stemness

Jingjing Wang, Lili Tian, Muhammad Noman Khan et al. · Cancer Letters · 2017 · 139 citations

Medicine, Oncology, Pharmacology +16